A Call to Action Against Persistent Lack of Transparency in Vaccine Pricing Practices During the COVID-19 Pandemic
Open Access
- 11 October 2022
- journal article
- research article
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 88 (1) , 1-6
Abstract
Lack of transparency in vaccine pricing practices is a problem that has been under discussion for a long time. To tackle this, the World Health Assembly adopted the resolution Improving the transparency of markets for medicines, vaccines, and other health products in 2019. However, despite the appalling effects of the current pandemic and the unequal global distribution of vaccines, the 2019 resolution has not been included as a fundamental pillar in the global health response to COVID-19.Keywords
This publication has 14 references indexed in Scilit:
- Leave no one behind: ensuring access to COVID-19 vaccines for refugee and displaced populationsNature Medicine, 2021
- Transparency in Negotiation of European Union With Big Pharma on COVID-19 VaccinesFrontiers in Public Health, 2021
- Covid-19: Countries are learning what others paid for vaccinesBMJ, 2021
- Vaccine nationalism's politicsScience, 2020
- Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999-2018JAMA Internal Medicine, 2020
- Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonusThe Journal of Antibiotics, 2020
- Pricing of pharmaceuticals is becoming a major challenge for health systemsBMJ, 2020
- Pharmaceutical High Profits: The Value of R&D, or Oligopolistic Rents?The American Journal of Economics and Sociology, 2012
- Pricing of new vaccinesHuman Vaccines, 2010
- Ethical issues in funding orphan drug research and developmentJournal of Medical Ethics, 2005